H.R. 7515 · 117th Congress · House

Infectious Disease Therapies Research and Innovation Act of 2022

Active· Referred to the House Committee on Ways and Means.
Introduced
Apr 14, 22
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Infectious Disease Therapies Research and Innovation Act of 2022

This bill exempts from the definition of passive activity, for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity.

The bill defines specified medical research small business pass-thru entity as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than $1 million.

Action Timeline

3
  1. APR 14, 2022IntroReferral

    Introduced in House

  2. APR 14, 2022IntroReferral

    Introduced in House

  3. APR 14, 2022IntroReferral

    Referred to the House Committee on Ways and Means.

Committees

1

Ways and Means Committee

hswm00

Referred: Apr 14, 2022

Active